Graeme A Macdonald

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7626098/publications.pdf

Version: 2024-02-01

121 papers 6,128 citations

94381 37 h-index 71651 76 g-index

127 all docs

127 docs citations

times ranked

127

7481 citing authors

#	Article	IF	CITATIONS
1	Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology, 1998, 114, 311-318.	0.6	636
2	Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology, 1999, 29, 1215-1219.	3.6	623
3	Adiponectin - a key adipokine in the metabolic syndrome. Diabetes, Obesity and Metabolism, 2006, 8, 264-280.	2.2	543
4	Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut, 2002, 51, 89-94.	6.1	259
5	Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 2092-2103.e6.	2.4	237
6	Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. British Journal of Surgery, 2002, 87, 1197-1202.	0.1	189
7	Effect of Hookworm Infection on Wheat Challenge in Celiac Disease – A Randomised Double-Blinded Placebo Controlled Trial. PLoS ONE, 2011, 6, e17366.	1.1	188
8	Adiponectin Multimerization Is Dependent on Conserved Lysines in the Collagenous Domain: Evidence for Regulation of Multimerization by Alterations in Posttranslational Modifications. Molecular Endocrinology, 2006, 20, 1673-1687.	3.7	162
9	Review of genetic and epigenetic alterations in hepatocarcinogenesis. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 15-21.	1.4	141
10	Impact of Diabetes on the Severity of Liver Disease. American Journal of Medicine, 2007, 120, 829-834.	0.6	139
11	Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 599-606.	1.4	134
12	Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. Journal of Hepatology, 2001, 34, 314-320.	1.8	133
13	Leptin and the risk of Barrett's oesophagus. Gut, 2007, 57, 448-454.	6.1	126
14	Exercise capacity and muscle strength in patients with cirrhosis. Liver Transplantation, 2012, 18, 146-151.	1.3	109
15	Sertraline treatment of interferonâ€alfaâ€induced depressive disorder. Medical Journal of Australia, 2000, 173, 359-361.	0.8	107
16	Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology, 1998, 28, 90-97.	3.6	101
17	EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene, 2003, 22, 5070-5081.	2.6	95
18	Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut, 2013, 62, 1625-1633.	6.1	87

#	Article	IF	Citations
19	Detection of male DNA in the liver of female patients with primary biliary cirrhosis. Journal of Hepatology, 2000, 33, 690-695.	1.8	86
20	Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease. Journal of Hepatology, 2010, 53, 841-848.	1.8	85
21	Symptom Prevalence and Clustering of Symptoms in People Living with Chronic Hepatitis C Infection. Journal of Pain and Symptom Management, 2006, 31, 335-344.	0.6	79
22	Glucose uptake and insulin action in human adipose tissueâ€"influence of BMI, anatomical depot and body fat distribution. International Journal of Obesity, 2002, 26, 17-23.	1.6	69
23	Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. Gut, 2005, 54, 103-108.	6.1	59
24	Olanzapine Treatment is Associated with Reduced High Molecular Weight Adiponectin in Serum. Journal of Clinical Psychopharmacology, 2006, 26, 232-237.	0.7	59
25	The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. Liver International, 2012, 32, 1391-1399.	1.9	55
26	Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease. Seminars in Liver Disease, 2017, 37, 388-400.	1.8	55
27	High Molecular Weight Adiponectin Correlates with Insulin Sensitivity in Patients with Hepatitis C Genotype 3, But Not Genotype 1 Infection. American Journal of Gastroenterology, 2005, 100, 2717-2723.	0.2	52
28	Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Seminars in Liver Disease, 2019, 39, 432-441.	1.8	52
29	Pathogenesis of Hepatocellular Carcinoma. Clinics in Liver Disease, 2001, 5, 69-85.	1.0	50
30	Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. American Journal of Gastroenterology, 2020, 115, 814-822.	0.2	48
31	The role of Doppler left ventricular filling indexes and Doppler tissue echocardiography in the assessment of cardiac involvement in hereditary hemochromatosis. Journal of the American Society of Echocardiography, 2002, 15, 884-890.	1.2	46
32	Living with chronic hepatitis C means 'you just haven't got a normal life any more'. Chronic Illness, 2006, 2, 121-131.	0.6	46
33	Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years. European Heart Journal Quality of Care & Dinical Outcomes, 2020, 6, 243-253.	1.8	45
34	p73 Is up-regulated in a subset of hepatocellular carcinomas. Hepatology, 2000, 31, 601-605.	3.6	44
35	Mini-microabscess syndrome in liver transplant recipients. Hepatology, 1997, 26, 192-197.	3.6	43
36	Sialic Acid Modification of Adiponectin Is Not Required for Multimerization or Secretion but Determines Half-Life in Circulation. Molecular Endocrinology, 2010, 24, 229-239.	3.7	43

#	Article	IF	Citations
37	Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Medical Journal of Australia, 2011, 194, 398-402.	0.8	42
38	Assessment of hepatic steatosis: comparison of quantitative and semiquantitative methods in 108 liver biopsies. Liver International, 2009, 29, 530-535.	1.9	39
39	Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. Progress in Cardiovascular Diseases, 2019, 62, 127-134.	1.6	38
40	The risk of Barrett's esophagus associated with abdominal obesity in males and females. International Journal of Cancer, 2013, 132, 2192-2199.	2.3	37
41	HLAâ€DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers. International Journal of Cancer, 2009, 125, 1231-1237.	2.3	35
42	Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. Liver Transplantation, 2019, 25, 25-34.	1.3	35
43	No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 1188-1191.	1.4	30
44	Additive impact of preâ€liver transplant metabolic factors on survival postâ€liver transplant. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1016-1024.	1.4	30
45	Severe acute liver injury associated with lumiracoxib. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1102-1105.	1.4	28
46	Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 155-167.	1.9	28
47	Altered clot kinetics in patients with non-alcoholic fatty liver disease. Annals of Hepatology, 2009, 8, 331-338.	0.6	27
48	Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 2012, 196, 633-637.	0.8	27
49	Cerebral benzodiazepine receptor bindingin vivo in patients with recurrent hepatic encephalopathy. Hepatology, 1997, 26, 277-282.	3.6	26
50	Is vitamin E beneficial in chronic liver disease?. Hepatology, 2007, 46, 288-290.	3.6	26
51	The Labyrinthine Ways of Cancer Immunotherapy–T Cell, Tumor Cell Encounter: "How Do I Lose Thee? Let Me Count the Ways― Advances in Cancer Research, 1998, 75, 203-249.	1.9	23
52	Telehealth-delivered, Cardioprotective Diet and Exercise Program for Liver Transplant Recipients: A Randomized Feasibility Study. Transplantation Direct, 2021, 7, e667.	0.8	23
53	Fat oxidation over a range of exercise intensities: fitness versus fatness. Applied Physiology, Nutrition and Metabolism, 2014, 39, 1352-1359.	0.9	22
54	More clues to the relationship between hepatic iron and steatosis: An association with insulin resistance?. Gastroenterology, 1999, 117, 1241-1244.	0.6	21

#	Article	IF	CITATIONS
55	Changes in dietary patterns and body composition within 12 months of liver transplantation. Hepatobiliary Surgery and Nutrition, 2017, 6, 317-326.	0.7	20
56	Fulminant hepatitis in patients undergoing liver transplantation: Evidence for a non-A, non-B, non-C, non-D, and non-E syndrome. Liver Transplantation, 1996, 2, 60-66.	1.9	19
57	Safety, adherence and efficacy of exercise training in solid-organ transplant candidates: A systematic review. Transplantation Reviews, 2016, 30, 218-226.	1.2	19
58	Peroxisomal fatty acid metabolism, peroxisomal proliferator-activated receptors and non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 1335-1337.	1.4	18
59	Magnetic resonance imaging (MRI) and diseases of the liver and biliary tract. Part 1. Basic principles, MRI in the assessment of diffuse and focal hepatic disease. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 980-991.	1.4	17
60	General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community setting. Australian Journal of Primary Health, 2011, 17, 282.	0.4	17
61	Exercise Training Is Safe and Feasible in Patients Awaiting Liver Transplantation: A Pilot Randomized Controlled Trial. Liver Transplantation, 2019, 25, 1576-1580.	1.3	17
62	Management of Patients With Erythropoietic Protoporphyria–Related Progressive Liver Disease. Liver Transplantation, 2019, 25, 1620-1633.	1.3	17
63	â€~Back to Life'—Using knowledge exchange processes to enhance lifestyle interventions for liver transplant recipients: A qualitative study. Nutrition and Dietetics, 2019, 76, 399-406.	0.9	17
64	Liver transplant recipients' experiences and perspectives of a telehealth-delivered lifestyle programme: A qualitative study. Journal of Telemedicine and Telecare, 2021, 27, 590-598.	1.4	17
65	Survival following Fulminant Hepatic Failure from Fluconazole Induced Hepatitis. Anaesthesia and Intensive Care, 1999, 27, 650-653.	0.2	16
66	Reciprocal relationship between methylation status and loss of heterozygosity at the p14ARF locus in Australian and South African hepatocellular carcinomas. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 301-307.	1.4	16
67	Symptoms of Obstructive Sleep Apnea, Gastroesophageal Reflux and the Risk of Barrett's Esophagus in a Population-Based Case-Control Study. PLoS ONE, 2015, 10, e0129836.	1.1	16
68	<scp>NAFLD</scp> in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by ¹ Hâ€ <scp>MRS</scp> ?. Liver International, 2017, 37, 1907-1915.	1.9	16
69	Telementoring for hepatitis C treatment in correctional facilities. Journal of Telemedicine and Telecare, 2018, 24, 690-696.	1.4	15
70	Hemochromatosis mutation in hepatitis C: Histopathology. Gastroenterology, 1998, 115, 1307-1308.	0.6	14
71	Total body fat and the risk of Barrett's oesophagus – A bioelectrical impedance study. Cancer Epidemiology, 2014, 38, 266-272.	0.8	14
72	Excellent Contemporary Graft Survival for Adult Liver Retransplantation: An Australian and New Zealand Registry Analysis From 1986 to 2017. Transplantation Direct, 2019, 5, e472.	0.8	14

#	Article	IF	CITATIONS
73	Influence of Altered Blood Rheology on Ventricular-Vascular Response to Exercise. Hypertension, 2009, 54, 1092-1098.	1.3	13
74	Dysbiosis of the Duodenal Mucosal Microbiota Is Associated With Increased Small Intestinal Permeability in Chronic Liver Disease. Clinical and Translational Gastroenterology, 2019, 10, e00068.	1.3	13
75	Why do we not yet have combination chemotherapy for chronic hepatitis B?. Medical Journal of Australia, 2007, 186, 204-206.	0.8	12
76	Raised alanine transaminase and decreased adiponectin are features of the metabolic syndrome in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2007, 9, 438-440.	2.2	12
77	Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C. Australian Health Review, 2013, 37, 218.	0.5	12
78	Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease?. Diabetes Research and Clinical Practice, 2008, 80, e10-e12.	1.1	11
79	Three-Dimensional Electromagnetic Torso Scanner. Sensors, 2019, 19, 1015.	2.1	11
80	Wearable Electromagnetic Belt for Steatotic Liver Detection Using Multivariate Energy Statistics. IEEE Access, 2020, 8, 201847-201860.	2.6	11
81	â€~Focus on diet quality': a qualitative study of clinicians' perspectives of use of the Mediterranean dietary pattern for non-alcoholic fatty liver disease. British Journal of Nutrition, 2021, , 1-11.	1.2	10
82	Liverâ€related mortality in countries of the developed world: an ecological study approach to explain the variability. Alimentary Pharmacology and Therapeutics, 2016, 44, 68-77.	1.9	9
83	Magnetic resonance imaging and diseases of the liver and biliary tract. Part 2. Magnetic resonance cholangiography and angiography and conclusions. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 992-999.	1.4	8
84	Value of the 8-oxodG/dG ratio in chronic liver inflammation of patients with hepatocellular carcinoma. Redox Biology, 2016, 8, 259-270.	3.9	8
85	Altered clot kinetics in patients with non-alcoholic fatty liver disease. Annals of Hepatology, 2009, 8, 331-8.	0.6	8
86	Cadherin/catenin complex appears to be intact in hepatocellular carcinomas from Australia and South Africa. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 676-682.	1.4	7
87	Varying etiologies lead to different molecular changes in Australian and South African hepatocellular carcinomas. International Journal of Oncology, 2009, 35, 1081-9.	1.4	7
88	Agreement and Reliability of Clinician-in-Clinic Versus Patient-at-Home Clinical and Functional Assessments: Implications for Telehealth Services. Archives of Rehabilitation Research and Clinical Translation, 2020, 2, 100066.	0.5	7
89	Evaluation of techniques used to assess skeletal muscle quantity in patients with cirrhosis. Clinical Nutrition ESPEN, 2021, 44, 287-296.	0.5	7
90	Diet and Liver Disease â€" A Glimpse into the Future. Journal of Clinical Gastroenterology, 1994, 18, 274-276.	1.1	6

#	Article	IF	Citations
91	Hepatocellular carcinoma. Current Opinion in Gastroenterology, 2000, 16, 275-281.	1.0	6
92	What Is the Optimal Dietary Composition for NAFLD?. Current Hepatology Reports, 2017, 16, 346-355.	0.4	6
93	Sex Differences in the Risk of Barrett's Esophagus Associated With the Metabolic Effects of Obesity. Journal of Clinical Gastroenterology, 2020, 54, 795-800.	1.1	6
94	A Pilot Randomised Study of the Metabolic and Histological Effects of Exercise in Non-alcoholic Steatohepatitis. Journal of Diabetes & Metabolism, 2013, 04, .	0.2	6
95	Impact of betaâ€blockers on cardiopulmonary exercise testing in patients with advanced liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 741-747.	1.9	5
96	Computerised tomography skeletal muscle and adipose surface area values in a healthy Caucasian population. European Journal of Clinical Nutrition, 2020, 74, 1276-1281.	1.3	5
97	Independent effects of diet and exercise training on fat oxidation in non-alcoholic fatty liver disease. World Journal of Hepatology, 2016, 8, 1137.	0.8	5
98	Clinician Perspectives of Barriers and Enablers to Implementing the Mediterranean Dietary Pattern in Routine Care for Coronary Heart Disease and Type 2 Diabetes: A Qualitative Interview Study. Journal of the Academy of Nutrition and Dietetics, 2022, 122, 1263-1282.	0.4	5
99	Utilizing Technology for Diet and Exercise Change in Complex Chronic Conditions Across Diverse Environments (U-DECIDE): Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2022, 11, e37556.	0.5	5
100	Iron and fibrosis in nonalcoholic fatty liver disease. Hepatology, 2000, 31, 549-549.	3.6	4
101	Chronic hepatitis E infection in an immunosuppressed, solid organ transplant patient. Internal Medicine Journal, 2019, 49, 1335-1336.	0.5	4
102	Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0. Cancers, 2022, 14, 2777.	1.7	4
103	Weightâ€based tacrolimus trough concentrations post liver transplant. Internal Medicine Journal, 2019, 49, 79-83.	0.5	3
104	Poor Cardiorespiratory Fitness Is a Risk Factor for Sepsis in Patients Awaiting Liver Transplantation. Transplantation, 2019, 103, 529-535.	0.5	3
105	Hepatic Steatosis Detection Using Differential Effective Permittivity. IEEE Transactions on Antennas and Propagation, 2021, 69, 8842-8853.	3.1	3
106	Silencing of O6-methylguanine DNA methyltransferase in the absence of promoter hypermethylation in hepatocellular carcinomas from Australia and South Africa. Oncology Reports, 2007, 17, 817-22.	1.2	3
107	Triage of referrals to outpatient hepatology services: an ineffective tool to prioritise patients?. Australian Health Review, 2012, 36, 443.	0.5	2
108	Tu1709 Altered Proximal Small-Intestinal Permeability and Bacterial Translocation in Chronic Liver Disease in Relation to Hepatic Fibrosis and Disease Severity. Gastroenterology, 2016, 150, S1169.	0.6	2

#	Article	IF	CITATIONS
109	Is post-transplant metabolic syndrome associated with pre-liver transplant visceral adipose tissue area?. Clinical Nutrition ESPEN, 2020, 39, 61-66.	0.5	2
110	Induction of Meal-related Symptoms as a Novel Mechanism of Action of the Duodenal-Jejunal Bypass Sleeve. Journal of Clinical Gastroenterology, 2020, 54, 528-535.	1.1	2
111	The inter―and intrarater reliability and feasibility of dietetic assessment of sarcopenia and frailty in potential liver transplant recipients: A mixedâ€methods study. Clinical Transplantation, 2021, 35, e14185.	0.8	2
112	A Qualitative Study of Clinician Barriers and Enablers to Implementing the Mediterranean Dietary Pattern with Kidney and Liver Transplant Recipients. Progress in Transplantation, 2021, 31, 337-344.	0.4	2
113	Augmentation of Meal-Related Symptoms following Placement of Duodenal-Jejunal Bypass Sleeve is a Potential Mechanism of Action Inducing Weight Loss. Gastroenterology, 2017, 152, S638.	0.6	1
114	Hepatocellular carcinoma. Current Opinion in Gastroenterology, 1999, 15, 253-259.	1.0	1
115	Weight reduction in patients with chronic HCV reduces circulating insulin levels. Journal of Hepatology, 2002, 36, 255-256.	1.8	0
116	A case of periportal fibrosis in a Sudanese refugee. Medical Journal of Australia, 2008, 188, 677-678.	0.8	0
117	1100 Chronic Hepatitis C Is Associated With Dysbiosis of the Small Intestinal Microbiota and Altered Intestinal Permeability. Gastroenterology, 2016, 150, S220-S221.	0.6	0
118	The Oxygen Uptake Efficiency Slope Is Not Influenced By Beta-blockade In End-stage Liver Disease Patients. Medicine and Science in Sports and Exercise, 2016, 48, 711.	0.2	0
119	Tu1690 Liver-Related Mortality in Countries of the Developed World: An Ecological Study Approach to Explain the Variability. Gastroenterology, 2016, 150, S926.	0.6	0
120	Improvements of Liver and Glycaemic Parameters after Duodenal-Jejunal Bypass Sleeve (DJBS) Insertion. Gastroenterology, 2017, 152, S638.	0.6	0
121	Fiveâ€year conditional survival for patients with hepatocellular carcinoma in Queensland, Australia. GastroHep, 2019, 1, 61-69.	0.3	O